NASDAQ:EAR

Eargo Competitors

$46.67
-0.34 (-0.72 %)
(As of 04/19/2021 11:04 AM ET)
Add
Compare
Today's Range
$46.30
Now: $46.67
$47.01
50-Day Range
$43.80
MA: $52.58
$61.16
52-Week Range
$32.58
Now: $46.67
$76.75
Volume3,246 shs
Average Volume310,178 shs
Market Capitalization$1.79 billion
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Eargo (NASDAQ:EAR) Vs. MSA, AVNS, ESTA, INGN, SIEN, and IVC

Should you be buying EAR stock or one of its competitors? Companies in the industry of "surgical appliances & supplies" are considered alternatives and competitors to Eargo, including MSA Safety (MSA), Avanos Medical (AVNS), Establishment Labs (ESTA), Inogen (INGN), Sientra (SIEN), and Invacare (IVC).

Eargo (NASDAQ:EAR) and MSA Safety (NYSE:MSA) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, earnings, institutional ownership, dividends, analyst recommendations, valuation and profitability.

Institutional and Insider Ownership

77.2% of MSA Safety shares are held by institutional investors. 7.0% of MSA Safety shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for Eargo and MSA Safety, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eargo00403.00
MSA Safety01202.67

Eargo currently has a consensus price target of $48.00, indicating a potential upside of 2.85%. MSA Safety has a consensus price target of $151.50, indicating a potential downside of 2.23%. Given Eargo's stronger consensus rating and higher probable upside, equities research analysts plainly believe Eargo is more favorable than MSA Safety.

Earnings and Valuation

This table compares Eargo and MSA Safety's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EargoN/AN/AN/AN/AN/A
MSA Safety$1.40 billion4.32$136.44 million$4.8032.29

MSA Safety has higher revenue and earnings than Eargo.

Profitability

This table compares Eargo and MSA Safety's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EargoN/AN/AN/A
MSA Safety10.40%23.96%10.13%

Summary

MSA Safety beats Eargo on 6 of the 9 factors compared between the two stocks.

Avanos Medical (NYSE:AVNS) and Eargo (NASDAQ:EAR) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, dividends, risk, profitability, analyst recommendations and institutional ownership.

Profitability

This table compares Avanos Medical and Eargo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Avanos Medical1.93%3.20%2.28%
EargoN/AN/AN/A

Institutional and Insider Ownership

94.8% of Avanos Medical shares are held by institutional investors. 1.5% of Avanos Medical shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares Avanos Medical and Eargo's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Avanos Medical$697.60 million3.05$-45,900,000.00$1.0741.39
EargoN/AN/AN/AN/AN/A

Eargo has lower revenue, but higher earnings than Avanos Medical.

Analyst Recommendations

This is a breakdown of recent recommendations for Avanos Medical and Eargo, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Avanos Medical10102.00
Eargo00403.00

Avanos Medical currently has a consensus target price of $50.00, indicating a potential upside of 11.16%. Eargo has a consensus target price of $48.00, indicating a potential upside of 2.85%. Given Avanos Medical's higher possible upside, equities analysts plainly believe Avanos Medical is more favorable than Eargo.

Summary

Avanos Medical beats Eargo on 7 of the 9 factors compared between the two stocks.

Eargo (NASDAQ:EAR) and Establishment Labs (NASDAQ:ESTA) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, risk, dividends, institutional ownership, profitability, valuation and analyst recommendations.

Insider & Institutional Ownership

54.8% of Establishment Labs shares are owned by institutional investors. 2.6% of Establishment Labs shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent ratings and price targets for Eargo and Establishment Labs, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Eargo00403.00
Establishment Labs01302.75

Eargo currently has a consensus price target of $48.00, indicating a potential upside of 2.85%. Establishment Labs has a consensus price target of $46.00, indicating a potential downside of 31.09%. Given Eargo's stronger consensus rating and higher probable upside, equities research analysts plainly believe Eargo is more favorable than Establishment Labs.

Valuation and Earnings

This table compares Eargo and Establishment Labs' top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
EargoN/AN/AN/AN/AN/A
Establishment Labs$89.57 million17.65$-38,150,000.00($1.86)-35.89

Eargo has higher earnings, but lower revenue than Establishment Labs.

Profitability

This table compares Eargo and Establishment Labs' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
EargoN/AN/AN/A
Establishment Labs-46.40%-49.51%-24.21%

Summary

Eargo beats Establishment Labs on 6 of the 9 factors compared between the two stocks.

Inogen (NASDAQ:INGN) and Eargo (NASDAQ:EAR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, risk, dividends, profitability, valuation, earnings and institutional ownership.

Insider & Institutional Ownership

95.1% of Inogen shares are owned by institutional investors. 4.8% of Inogen shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current recommendations for Inogen and Eargo, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inogen03102.25
Eargo00403.00

Inogen currently has a consensus target price of $63.00, indicating a potential downside of 0.25%. Eargo has a consensus target price of $48.00, indicating a potential upside of 2.85%. Given Eargo's stronger consensus rating and higher probable upside, analysts clearly believe Eargo is more favorable than Inogen.

Valuation & Earnings

This table compares Inogen and Eargo's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inogen$361.94 million3.90$20.95 million$1.0759.03
EargoN/AN/AN/AN/AN/A

Inogen has higher revenue and earnings than Eargo.

Profitability

This table compares Inogen and Eargo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inogen-0.66%0.21%0.16%
EargoN/AN/AN/A

Summary

Inogen beats Eargo on 5 of the 9 factors compared between the two stocks.

Sientra (NASDAQ:SIEN) and Eargo (NASDAQ:EAR) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Profitability

This table compares Sientra and Eargo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Sientra-123.88%-174.05%-38.97%
EargoN/AN/AN/A

Analyst Recommendations

This is a breakdown of current ratings for Sientra and Eargo, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Sientra00403.00
Eargo00403.00

Sientra presently has a consensus target price of $10.00, indicating a potential upside of 44.93%. Eargo has a consensus target price of $48.00, indicating a potential upside of 2.85%. Given Sientra's higher probable upside, equities research analysts plainly believe Sientra is more favorable than Eargo.

Insider and Institutional Ownership

71.0% of Sientra shares are owned by institutional investors. 2.8% of Sientra shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Sientra and Eargo's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sientra$83.70 million4.74$-106,820,000.00($2.29)-3.02
EargoN/AN/AN/AN/AN/A

Eargo has lower revenue, but higher earnings than Sientra.

Summary

Sientra beats Eargo on 4 of the 7 factors compared between the two stocks.

Invacare (NYSE:IVC) and Eargo (NASDAQ:EAR) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, valuation, dividends, institutional ownership, profitability and risk.

Profitability

This table compares Invacare and Eargo's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Invacare-4.87%-8.76%-3.07%
EargoN/AN/AN/A

Insider & Institutional Ownership

96.7% of Invacare shares are held by institutional investors. 3.2% of Invacare shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Invacare and Eargo's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Invacare$927.96 million0.32$-53,330,000.00($1.06)-8.04
EargoN/AN/AN/AN/AN/A

Eargo has lower revenue, but higher earnings than Invacare.

Analyst Recommendations

This is a summary of recent ratings and price targets for Invacare and Eargo, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Invacare00103.00
Eargo00403.00

Invacare presently has a consensus price target of $17.00, suggesting a potential upside of 99.53%. Eargo has a consensus price target of $48.00, suggesting a potential upside of 2.85%. Given Invacare's higher possible upside, equities research analysts clearly believe Invacare is more favorable than Eargo.


Eargo Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
MSA Safety logo
MSA
MSA Safety
2.1$154.99-0.4%$6.08 billion$1.40 billion43.91
Avanos Medical logo
AVNS
Avanos Medical
1.5$44.29-1.6%$2.16 billion$697.60 million152.72
Establishment Labs logo
ESTA
Establishment Labs
1.2$66.75-3.7%$1.63 billion$89.57 million-39.50Decrease in Short Interest
Inogen logo
INGN
Inogen
1.2$63.16-4.1%$1.47 billion$361.94 million-701.70Analyst Revision
Sientra logo
SIEN
Sientra
1.6$6.92-2.2%$404.92 million$83.70 million-3.89Analyst Downgrade
Increase in Short Interest
Invacare logo
IVC
Invacare
1.6$8.52-3.2%$302.59 million$927.96 million-6.93
SMTI
Sanara MedTech
0.8$29.32-3.2%$230.41 million$11.77 million-22.73Decrease in Short Interest
News Coverage
Lakeland Industries logo
LAKE
Lakeland Industries
1.8$27.67-1.1%$219.43 million$107.81 million7.86Earnings Announcement
Analyst Report
Gap Down
Surgalign logo
SRGA
Surgalign
1.7$1.83-3.6%$208.41 million$308.38 million-1.01Increase in Short Interest
Surgalign logo
SRGA
Surgalign
1.4$1.83-3.6%$208.41 million$308.38 million-1.01Increase in Short Interest
Conformis logo
CFMS
Conformis
1.3$0.82-3.3%$154.50 million$77.43 million-2.41
ReWalk Robotics logo
RWLK
ReWalk Robotics
1.4$1.75-5.1%$84.81 million$4.87 million-1.39
CollPlant Biotechnologies logo
CLGN
CollPlant Biotechnologies
1.1$14.45-0.0%$81.93 million$2.32 million-7.23Gap Up
Predictive Oncology logo
POAI
Predictive Oncology
1.3$0.99-9.6%$52.70 million$1.41 million-0.16Gap Up
AHPI
Allied Healthcare Products
0.5$4.40-1.8%$17.97 million$31.89 million0.00Gap Up
NanoVibronix logo
NAOV
NanoVibronix
0.5$0.82-4.3%$11.39 million$530,000.00-1.36Decrease in Short Interest
Gap Up
This page was last updated on 4/19/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.